Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral inflammation and persistent immune activation within the central nervous ...

In a recent case report published in Frontiers in Immunology, scientists in Canada ... and brain health in two individuals with multiple sclerosis. These initial findings, based on brain scans ...

The Breakthrough Prizes have been awarded annually since 2013 to recognize accomplishments in fundamental physics, mathematics and the life sciences. One of the three life-science prizes recognizes ...

A new study published in Multiple Sclerosis and Related Disorders highlights the potential of "More Stamina," a gamified mobile health (mHealth) app designed to help people with multiple sclerosis ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple ...

An American neurologist and an Italian epidemiologist whose work revolutionized the treatment of multiple sclerosis on ...

Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

A new artificial intelligence (AI) tool called MindGlide was found to accurately calculate MS-related brain damage using a ...

Long-term data from the VISIONARY-MS Phase 2 trial links improved brain imaging and visual evoked potentials to remyelination and neuronal repair in MS patients treated with CNM-Au8.

Later, while pursuing a PhD in epidemiology, Ascherio shifted his focus to MS. “Multiple sclerosis is a very intriguing disease. It’s very rare in the tropics, so in the places where I was working, ...

The findings reinforce the potential of BRIUMVI in improving patient outcomes for those seeking an alternative to their previous anti-CD20 therapy. Furthermore, the article in CNS DRUGS offers an ...